A5057293622- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Cancer Genomics and Diagnostics
- Cancer-related gene regulation
- Chronic Lymphocytic Leukemia Research
- Epigenetics and DNA Methylation
- Renal Diseases and Glomerulopathies
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- HIV/AIDS drug development and treatment
- Cutaneous lymphoproliferative disorders research
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Ovarian cancer diagnosis and treatment
- Lung Cancer Treatments and Mutations
- Fungal Infections and Studies
- Glycosylation and Glycoproteins Research
- RNA modifications and cancer
- Genomics and Rare Diseases
- Genomics and Chromatin Dynamics
- Sarcoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Genetic factors in colorectal cancer
- Dermatological and COVID-19 studies
King's College Hospital
2024-2025
Queen Mary University of London
2018-2024
Zero to Three
2021
University College London
2020
University College London Hospitals NHS Foundation Trust
2020
Imperial College Healthcare NHS Trust
2015-2016
Imperial College London
2015-2016
Haematology patients receiving chemo- or immunotherapy are considered to be at greater risk of COVID-19-related morbidity and mortality. We aimed identify factors for COVID-19 severity assess outcomes in where complicated the treatment their haematological disorder. A retrospective cohort study was conducted 55 with disorders COVID-19, including 52 malignancy, two bone marrow failure one immune-mediated thrombotic thrombocytopenic purpura (TTP). diagnosis coincided a new malignancy four...
The pathogenesis and natural history of HIV-associated immune complex kidney disease (HIVICK) is not well understood. Key questions remain unanswered, including the role HIV infection replication in development efficacy antiretroviral therapy (ART) prevention treatment disease. In this multicentre study, we describe renal pathology HIVICK compare clinical characteristics patients with those IgA nephropathy (HIVAN). Poisson regression models were used to identify risk factors for each these...
Data on the impact of ethnic and socioeconomic factors Chimeric antigen receptor (CAR) T-cell therapy (access outcomes are limited, but key to understand whether results from registration trials generalizable real-world patient populations. Here, we analysed ethnicity, deprivation referral patterns in a cohort 314 large B-cell lymphoma patients approved for third-line CD19 CAR-T across three UK centres. Patients deprived areas had lower infusion rate compared low (73% vs. 86%, p = 0.04)....
To describe the spectrum of renal tubular disease (RTD) in HIV-positive patients and its association with exposure to antiretroviral therapy (ART).Review 265 consecutive biopsies from attending eight clinics United Kingdom between 2000 2012.We described clinical characteristics RTD compared current/recent (at time of, or up 3 months prior date biopsy) potentially nephrotoxic ART [tenofovir (TDF), atazanavir (ATV), indinavir (IDV) lopinavir/ritonavir (LPV/r)]. We also analysed incidence UK...
Despite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack biomarker-directed therapeutic approaches in routine practice, with notable exception EZH2 inhibitor tazemetostat EZH2-mutant FL. Here we examined whether gene mutation status predicts response to mTOR inhibitors (mTORi) FL, by performing targeted mutational profiling biopsies from 21 relapsed/refractory FL patients treated mTORi everolimus or temsirolimus within trials. We observed an...
Abstract Loss-of-function mutations in KMT2D are a striking feature of the germinal centre (GC) lymphomas, resulting decreased H3K4 methylation and altered gene expression. We hypothesised that inhibition KDM5 family, which demethylates H3K4me3/me2, would re-establish restore expression genes repressed upon loss . KDM5-inhibition increased H3K4me3 levels caused an anti-proliferative response vitro , was markedly greater both endogenous CRISPR-edited mutant DLBCL cell lines, whilst tumour...
Introduction: Although diffuse large B cell lymphoma (DLBCL) can be cured using immuno-chemotherapy, 40% of patients experience relapse or refractory disease. Large-scale profiling studies have mainly focused on DLBCL at diagnosis with a limited number longitudinal and no compelling biomarkers linked to identified. To address this, we utilized multifaceted approach integrating transcriptomic intratumoral T-cell repertoire analyses in paired diagnostic/relapse tumors enable identification...
Take home messages The genetic landscape of follicular lymphoma (FL) is skewed toward frequent mutations in epigenetic regulators. Divergent clonal evolution from a therapy-evading common progenitor cell proposed as the predominant mechanism underpinning relapse and transformation. Genomic studies are revealing new disease biomarkers therapeutic targets, with promise achieving precision medicine approach for subsets FL patients. Introduction Next-generation sequencing has improved our...
Background: With an expanding array of novel treatment options in follicular lymphoma (FL), we largely lack effective biomarkers to predict response this molecularly heterogeneous disease. Activating mutations focused on components the nutrient‐sensing arm mTORC1 pathway ( RRAGC, ATP6V1B2, ATP6AP1 ), are particularly enriched FL, occurring ∼30% cases. Meanwhile, clinical mTOR inhibitors (mTORi) have shown some promise, with rates 50–60% relapsed/refractory FL. Aims: We therefore sought...
Despite the effectiveness of immuno-chemotherapy, 40% patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on mutational landscape but fell short providing a consistent relapse-specific genetic signature. In our study, we attention changes in GEP accompanying DLBCL using archival paired diagnostic/relapse specimens from 38 de novo DLBCL. COO remained stable diagnosis to 80% patients, only single patient...